Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,269,816
  • Shares Outstanding, K 68,713
  • Annual Sales, $ 78,500 K
  • Annual Income, $ -367,300 K
  • EBIT $ -357 M
  • EBITDA $ -366 M
  • 60-Month Beta 1.82
  • Price/Sales 15.61
  • Price/Cash Flow N/A
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 102.85% ( +8.12%)
  • Historical Volatility 81.32%
  • IV Percentile 99%
  • IV Rank 87.31%
  • IV High 109.09% on 08/05/24
  • IV Low 59.89% on 05/01/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 69
  • Volume Avg (30-Day) 636
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 16,277
  • Open Int (30-Day) 8,695

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.07
  • Number of Estimates 11
  • High Estimate -0.22
  • Low Estimate -1.87
  • Prior Year -2.53
  • Growth Rate Est. (year over year) +57.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.37 +6.39%
on 12/19/24
27.00 -31.56%
on 11/29/24
-4.21 (-18.55%)
since 11/20/24
3-Month
17.37 +6.39%
on 12/19/24
29.61 -37.59%
on 10/30/24
-7.15 (-27.90%)
since 09/20/24
52-Week
17.37 +6.39%
on 12/19/24
53.08 -65.18%
on 02/16/24
-17.97 (-49.30%)
since 12/20/23

Most Recent Stories

More News
Arvinas and Pfizer Announce Encouraging Preliminary Phase 1b Results for Vepdegestrant Combined with Abemaciclib in Advanced ER+/HER2- Breast Cancer

Vepdegestrant combined with abemaciclib shows promising clinical activity and a favorable safety profile in advanced breast cancer patients.Quiver AI SummaryArvinas, Inc. and Pfizer Inc. announced promising...

ARVN : 18.48 (+3.65%)
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

ARVN : 18.48 (+3.65%)
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

ARVN : 18.48 (+3.65%)
Arvinas, Inc. to Present Clinical Data for Vepdegestrant at the 2024 San Antonio Breast Cancer Symposium

Arvinas will present three vepdegestrant posters at SABCS 2024, detailing its use in ER+/HER2- breast cancer.Quiver AI SummaryArvinas, Inc. announced the presentation of three posters detailing clinical...

ARVN : 18.48 (+3.65%)
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

ARVN : 18.48 (+3.65%)
Arvinas to Participate in Upcoming Investor Conferences

ARVN : 18.48 (+3.65%)
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ARVN : 18.48 (+3.65%)
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

ARVN : 18.48 (+3.65%)
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

ARVN : 18.48 (+3.65%)
OSI: Fiscal Q4 Earnings Snapshot

OSI: Fiscal Q4 Earnings Snapshot

ARVN : 18.48 (+3.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 20.11
2nd Resistance Point 19.41
1st Resistance Point 18.94
Last Price 18.48
1st Support Level 17.77
2nd Support Level 17.07
3rd Support Level 16.60

See More

52-Week High 53.08
Fibonacci 61.8% 39.44
Fibonacci 50% 35.23
Fibonacci 38.2% 31.01
Last Price 18.48
52-Week Low 17.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar